Questcor Pharmaceuticals has snapped up the rights to a Novartis drug that could have challenged its H.P. Acthar Gel product, which brought in $509 million last year, elbowing aside a startup company that wanted to roll out the Acthar rival at a price far, far lower than Questcor's.
As if last week's reimbursement blow to Questcor Pharmaceuticals wasn't enough, the company today disclosed that the U.S. government is investigating its marketing practices. The stock dropped by 27%, on top of a 40% decline last week.
Easy come, easy go? Questcor Pharmaceuticals ($QCOR) got a big boost yesterday after an Oppenheimer analyst raised his price target on the stock, citing Medicaid rebate changes that could boost sales of its Acthar drug by almost $100 million next year. Today, Aetna all but dropped its coverage of Acthar--and the stock plummeted.
Later this year, Questcor will be hit by a wave of new Medicaid rebate claims on its pricey drug Acthar as managed-care plans take advantage of a rebate provision tucked into the federal healthcare
Brian Orelli of The Motley Fool highlights four drugs--AstraZeneca's Brilinta, Questcor's Acthar Gel, Savient's Krystexxa and Novartis' Gilenia--that could gain FDA approval this month despite some
Xconomy has been digging into the regulatory paperwork to find out more about Evoke Pharma, a San Diego-based developer that's been operating in stealth mode. A quarterly report from Questcor shows
Prices have ballooned by 100 percent or more for a growing number of drugs, according to a new study. In fact, the number of branded meds whose prices have grown that much could double this year from
Congress raked some specialty pharma companies over the coals on Friday, accusing them of gouging patients with "staggeringly high prices." In a hearing, the Joint Economic Committee targeted
Drugmakers aren't the only ones making money off the specialty drug trend. Specialty drugs, many of